|Bid||0.0900 x 0|
|Ask||0.1050 x 0|
|Day's Range||0.0800 - 0.1050|
|52 Week Range||0.0650 - 0.1800|
|Beta (5Y Monthly)||0.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc. (CVE:AQS) since 2014. This report will, first, examine the...
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...
Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc. (CVE:AQS) since 2014. First, this article will compare CEO...